Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Latest Information Update: 23 Nov 2022
At a glance
- Drugs Crofelemer (Primary)
- Indications Chemotherapy-induced damage; Diarrhoea
- Focus Therapeutic Use
- Acronyms HALT-D
- 22 Nov 2022 Results assessing whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea, published in the Breast Cancer Research and Treatment
- 07 Jun 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2020 Planned End Date changed from 1 Jun 2020 to 1 Jan 2021.